The Conquer Cancer–Jazz HER2+ Gastroesophageal Adenocarcinoma (GEA) Quality Improvement Grant 2026 supports projects designed to improve equitable, guideline-concordant care for patients with advanced HER2-positive gastroesophageal adenocarcinoma in the United States.
The program focuses on practical quality improvement strategies that can increase appropriate use of HER2-directed therapy as part of first-line treatment. Individual projects may receive up to $125,000 over two years.
Eligibility Criteria
- Eligible applicants include U.S. healthcare delivery systems.
- Academic and community oncology delivery networks in the United States may apply.
- Only organizations and institutions may receive funding.
- The principal investigator must be an employee or contractor of the applying organization.
- Community cancer care providers are particularly encouraged to apply.
- Projects must focus on improving guideline-concordant care for advanced HER2+ GEA.
Funding Details
- Funding: Up to $125,000 per project
- Duration: 2 years
- Total funding available: $1 million
Deadline
- Applications opened: September 1, 2026
- Application deadline: October 15, 2026, at 11:59 PM ET
- Anticipated full proposal notification: End of November 2026
Further Information
- Applications must be submitted through the EveryGrant application portal.
- New applicants must create an EveryGrant account before submitting.
- Official Conquer Cancer–Jazz HER2+ GEA Quality Improvement Grant